| Today's Big NewsApr 21, 2023 |
|
An ideal home for reshoring. U.S. manufacturers gain greater control of and visibility into their supply chains, as well as access to a robust STEM talent pool, by setting up operations in Puerto Rico.
|
|
| By Fraiser Kansteiner In a new report, Bluebell urged Bayer to take things a step further after tapping Roche veteran Bill Anderson as the new CEO. With the appointment of a “credible, external CEO,” the German conglomerate should now turn its attention to “significantly” refreshing its supervisory board. |
|
|
|
By Conor Hale Activist investor Carl Icahn lodged a public proxy fight against the DNA sequencing giant in early March—largely over the company’s $8 billion acquisition of Grail and its resulting legal quarrels with antitrust regulators. |
By Max Bayer,Gabrielle Masson President Joe Biden will tap the current head of the National Cancer Institute and former cancer surgeon Monica Bertagnolli, M.D., to lead the National Institutes of Health. The move is the first permanent replacement for the federal institute after Francis Collins retired in 2021. |
By Kevin Dunleavy AbbVie and Johnson & Johnson’s Imbruvica may be losing popularity in the BTK inhibitor rivalry, but the two companies got a small victory as England’s NICE recommended Imbruvica in a combination for people with untreated chronic lymphocytic leukemia. |
|
Tuesday, May 23, 2023 | 2pm ET / 11am PT Clinical trials are complex, time-consuming, and costly. But what if you could use simulation to guide your decisions and optimize your trial design? In this webinar, we'll discuss the power of simulation-guided trial design (SGTD) and explain its benefits to clinical development strategies. Register now to join us.
|
|
By Angus Liu After a shortage prevented prostate cancer patients from getting Novartis’ Pluvicto, the FDA has quickly approved a radiotherapy manufacturing facility to help the company ramp up commercial supply. |
By Helen Floersh Jennifer Doudna's Innovative Genomics Institute will use a new $70 million grant from TED to develop gene editing and metagenomics tools to reduce greenhouse gases from cow burps. |
By Teresa Carey This week on "The Top Line," we talk about how Pfizer became the first company in Big Pharma history with $100 billion in sales. We also dive into a J&J data leak, Eli Lilly's manufacturing spending plan and more of this week's top headlines. |
By Andrea Park Know Labs is one step closer to bringing its noninvasive glucose monitoring technology to the masses. |
By Nick Paul Taylor Daiichi Sankyo’s long wait for approval of quizartinib just grew a little longer. Having bounced back from a 2019 rejection, the Japanese drugmaker has now learned the FDA needs another three months to review its second attempt to launch a challenger to Astellas and Novartis in a blood cancer market. |
By Fraiser Kansteiner In February, a federal judge said Merck & Co. and Glenmark Pharmaceuticals would have to face a jury trial over an alleged pay-for-delay deal tied to the cholesterol med Zetia. Now, two plaintiff groups have gotten in line behind settlement offers. But holdouts could still force Merck and Glenmark to defend themselves in court. |
By Andrea Park With preliminary first-quarter results showing a major boost in its revenues, Alphatec Holdings—the surgical device maker commonly known as ATEC Spine—has money to burn. |
By Nick Paul Taylor Boehringer Ingelheim has tapped RetinAI to support its attempt to develop treatments for geographic atrophy, striking a deal to apply AI tools to its imaging data in a search for novel biomarkers and predictors of disease progression. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we talk about how Pfizer became the first company in Big Pharma history with $100 billion in sales. We also dive into a J&J data leak, Eli Lilly's manufacturing spending plan and more of this week's top headlines. |
|
|---|
|
|
|
| Wednesday, April 26, 2023 | 12pm ET / 9am PT Our speakers will explore how science-based organizations are producing more data than ever before, and why digital transformation strategies to leverage this data, like AI and machine learning, require the right infrastructure of connected, searchable, and harmonized data. Register now. |
|
| ResearchStrategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies Sponsored by: H1 |
| WhitepaperHow can eConsent provide a more flexible approach to informed consent? Sponsored by: YPrime |
| WhitepaperThe preclinical hematotoxicity screening method that helps clients eliminate bad players earlier in the drug development process Sponsored by: ReachBio | The Cell Biology Experts™ |
| WhitepaperWe’ve identified four must-have tools to manage today’s scientific information chaos. How many are you utilizing? Sponsored By: CCC |
| WhitepaperHow advanced medicines commercial readiness differs and the resources needed to maximize potential. Sponsored by: Herspiegel Consulting |
| WhitepaperThis paper outlines an approach that digital health / therapeutics companies can use when developing a go-to-market strategy for the complex US market. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperPreparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| |
|
